![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Cimzia Gets Additional Indication for Psoriasis
Cimzia Gets Additional Indication for Psoriasis
The FDA approved UCB’s Cimzia (certolizumab pegol injection) for an expanded indication for moderate-to-severe plaque psoriasis.
The FDA cleared the additional indication based on phase 3 trials that found the drug significantly improved symptoms and the clinical benefit continued through 48 weeks.
The approval follows a recent update to Cimzia’s labeling for use in pregnancy and breastfeeding.
Upcoming Events
-
21Oct